The burden of aspergillosis, especially Chronic Pulmonary Aspergillosis, is increasingly recognized, and the increasing presence of azole-resistant environmental has been highlighted as a health risk. However, a sizable minority of aspergillosis is caused by , which is assumed to be sensitive to azoles but is infrequently included in surveillance. We conducted environmental sampling at 150 locations in a rural province of southern Vietnam. isolates were identified morphologically, their identity was confirmed by sequencing of the beta-tubulin gene, and then they were tested for susceptibility to azoles and amphotericin B according to EUCAST methodologies. We found that over 85% of isolates were resistant to at least one azole, and half of them were resistant to itraconazole. This unexpectedly high prevalence of resistance demands further investigation to determine whether it is linked to agricultural azole use, as has been described for . Clinical correlation is required, so that guidelines can be adjusted to take this information into account.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711995PMC
http://dx.doi.org/10.3390/jof6040296DOI Listing

Publication Analysis

Top Keywords

drug-resistant highly
4
highly prevalent
4
prevalent environment
4
environment vietnam
4
vietnam challenge
4
challenge management
4
management aspergillosis?
4
aspergillosis? burden
4
burden aspergillosis
4
aspergillosis chronic
4

Similar Publications

Systemic lupus erythematosus (SLE) is a typical autoimmune disease; although severe disease and refractoriness to existing therapies are still experienced, the number of cases resistant to remission induction has decreased with the establishment of various therapies. However, improving long-term prognosis remains a challenge due to the unavoidable prolonged use of non-selective glucocorticoids. To investigate the additional effect of belimumab in the chronic phase, we included 28 of 46 patients with SLE who were initiated on belimumab between January 2018 and October 2022 for glucocorticoid reduction.

View Article and Find Full Text PDF

Bacteriophage as a novel therapeutic approach for killing multidrug-resistant ST131 clone.

Front Microbiol

December 2024

Department of Biomedical Science, The Graduate School, Kyungpook National University, Daegu, Republic of Korea.

The emergence of the multidrug-resistant (MDR) ST131 clone has significantly impacted public health. With traditional antibiotics becoming less effective against MDR bacteria, there is an urgent need for alternative treatment options. This study aimed to isolate and characterize four lytic phages (EC.

View Article and Find Full Text PDF

Hyperglycemia-responsive nitric oxide-releasing biohybrid cryogels with cascade enzyme catalysis for enhanced healing of infected diabetic wounds.

J Control Release

December 2024

Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang 325011, China; Department of Periodontics, School & Hospital of Stomatology, Wenzhou Medical University, Wenzhou, Zhejiang 325027, China. Electronic address:

Diabetic wound infections are a frequent complication for diabetic patients, and conventional treatment for combating diabetic wound infections relies on antibiotics. However, the misuse and overuse of antibiotics have led to the emergence of drug-resistant bacteria, making these infections challenging to treat. Thus, there is an urgent need for alternative strategies to effectively manage diabetic wound infections.

View Article and Find Full Text PDF

The point mutation N642H of the signal transducer and activator of transcription 5B (STAT5B) protein is associated with aggressive and drug-resistant forms of leukemia. This mutation is thought to promote cancer due to hyperactivation of STAT5B caused by increased stability of the active, parallel dimer state. However, the molecular mechanism leading to this stabilization is not well understood as there is currently no structure of the parallel dimer.

View Article and Find Full Text PDF

Objective: Resistance to antiseizure medications (ASMs) is a major challenge in the treatment of patients with epilepsy. Despite numerous newly marketed ASMs, the proportion of drug-resistant people with epilepsy has not significantly decreased over the years. Therefore, novel and innovative seizure models for preclinical drug screening are highly desirable.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!